ALNY SEC Filings
SEC filings for ALNY. Annual and quarterly reports, 8-K events, Form 4 insider filings and 13D/G stake disclosures.
| Form | Filed | Accession |
|---|---|---|
| 8-K | Jul 30, 2026 | 0001178670-26-000060EDGAR |
| 8-KAIAlnylam Pharmaceuticals expanded its Board of Directors from ten to eleven members, electing Benjamin F. Cravatt, Ph.D. | May 27, 2026 | 0001628280-26-038499EDGAR |
| 8-K | Apr 30, 2026 | 0001628280-26-028601EDGAR |
| 8-K | Mar 4, 2026 | 0001628280-26-014728EDGAR |
| 8-K | Feb 12, 2026 | 0001628280-26-007491EDGAR |
| 8-K | Jan 12, 2026 | 0001628280-26-001755EDGAR |
| 8-K | Dec 11, 2025 | 0001193125-25-315047EDGAR |
| 8-K | Dec 3, 2025 | 0001628280-25-055084EDGAR |
| 8-KAIAlnylam reported Q3 2025 total net product revenues of $851 million, up 103% year-over-year, driven by TTR franchise revenues of $724 million (135% growth) led by AMVUTTRA's ATTR-CM launch. | Oct 30, 2025 | 0001628280-25-047342EDGAR |
SEC filings for companies related to ALNY
Never miss a ALNY filing.
Get an email when ALNY files its next 8-K, Form 4, 10-K or 10-Q with the SEC. Free, no account needed.
Free foreverNo account requiredOne-click unsubscribe
Source: SEC EDGAR.